Was This Acquisition a Smart Move for GlaxoSmithKline?

Was This Acquisition a Smart Move for GlaxoSmithKline?

Submitted by admin on May 15, 2022 - 11:10pm
Source: 
Motley Fool
News Tags: 
GSK
Sierra Oncology
momelotinib
bone marrow cancer
M&A
Headline: 
Was This Acquisition a Smart Move for GlaxoSmithKline?
snippet: 
  • Momelotinib could be a potent treatment for bone marrow cancer patients.
  • The drug candidate could also become a blockbuster for GlaxoSmithKline.
  • Shares of the drugmaker seems like a good long-term buy for investors.

Do Not Allow Advertisers to Use My Personal information